Asahi Kasei Bioprocess America

Name

Asahi Kasei Bioprocess America

Legal name

Asahi Kasei Life Science Corporation

Website

https://ak-bio.com

Company type

Private

Founded year

1989

Operating status

Operating

Headcount range

11–50 employees

Ownership category

akta.pro rank

Product category

Bioprocessing Equipment

NAICS

Pharmaceutical and Medicine Manufacturing (3254)

SIC

Laboratory Analytical Instruments (3826)

akta.pro primary industry

Bioprocess Development & Scale-Up/Scale-Down Platforms (DoE, high-throughput, modeling) (HLAAAJAF)

akta.pro secondary industries

Continuous Bioprocessing Technologies (perfusion, continuous chromatography, integrated lines) (HLAAAJAH), Upstream Bioprocessing Systems & Equipment (cell culture/fermentation, bioreactors, feeds/media) (HLAAAJAA), Bioprocess Consumables & Reagents (resins, membranes, media components, buffers) (HLAAAJAI)

Keywords

• Bioprocessing equipment
• Oligonucleotide manufacturing
• Peptide synthesis systems
• Tangential flow filtration
• Pharmaceutical manufacturing solutions

Headquarters

HQ city

Glenview

HQ country

United States

HQ region

North America

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Technology or R&D, Personnel, Operations, Marketing or Sales

Distribution channels1 record

Core offering

Asahi Kasei Bioprocess America manufactures and sells bioprocessing equipment and integrated systems for pharmaceutical manufacturing, focused on oligonucleotide and peptide synthesis. Core products include large-scale synthesis columns, the THESYS Cleavage & Deprotection and Tangential Flow Filtration Unit, and flow-through peptide synthesis technology offered through an exclusive global partnership with PeptiSystems. The company delivers automated, integrated manufacturing solutions to pharmaceutical, biotechnology, and contract manufacturing customers.

Product overview

Asahi Kasei Bioprocess America offers a portfolio of bioprocessing equipment and integrated systems for pharmaceutical manufacturing, particularly oligonucleotide and peptide synthesis. The core offerings include large-scale synthesis columns and flow-through synthesis technology, with the THESYS platform providing modular units such as the Cleavage & Deprotection Unit and Tangential Flow Filtration Unit that can be combined into an automated integrated system. Through an exclusive global partnership with PeptiSystems, the company combines its large-scale synthesis columns with PeptiSystems' flow-through technology to deliver an integrated peptide synthesis solution.

Differentiator

Problem solved

Functional benefit

Brands

• THESYS: THESYS Cleavage & Deprotection and Tangential Flow Filtration unit for oligonucleotide production

Products and services

• THESYS Cleavage & Deprotection and Tangential Flow Filtration Unit An integrated, automated bioprocessing system for oligonucleotide manufacturing that combines cleavage, deprotection, and tangential flow filtration into a single unit, enabling pharmaceutical and biotechnology manufacturers to increase throughput, reduce operational complexity, and save lab floor space.
• Large-Scale Synthesis Columns Industrial-scale synthesis columns designed for high-volume peptide and oligonucleotide manufacturing, used as part of the integrated peptide synthesis solution with PeptiSystems' flow-through technology.
• Integrated Peptide Synthesis Solution (PeptiSystems Partnership) Integrated peptide synthesis solution combining PeptiSystems' flow-through technology with Asahi Kasei Bioprocess America's large-scale synthesis columns under an exclusive global partnership, designed to improve manufacturing efficiency, reduce changeover times, and support high-performance peptide manufacturing at commercial scale.

Quantifiable outcome

• Increased oligo throughput and more efficient scale production
• +2 more outcomes

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

One partnership is on record.

• PeptiSystemsflagshipStrategic or Co-development Partner · 15 May 2025Exclusive global partnership to develop an integrated peptide synthesis solution combining PeptiSystems' flow-through technology with Asahi Kasei Bioprocess America's large-scale synthesis columns. The collaboration aims to improve manufacturing efficiency, reduce changeover times, and support high-performance peptide manufacturing at scale.

Scale indicators2 records

Recent moves4 records

Expansion highlights4 records

Emerging players

• ABEC: Specialty bioprocess equipment and process solutions provider focused on bioreactor systems and integrated biomanufacturing platforms. Comparable to AKBA in delivering integrated, fit-for-purpose bioprocess equipment to pharma manufacturers.
• BIA Separations (Sartorius subsidiary): Specialist in monolithic chromatography columns and purification technologies for oligonucleotides, peptides, and other complex biologics. Directly competes with AKBA's synthesis/column offering in nucleic acid and peptide purification niches.

Broad incumbents

• Cytiva: Broad bioprocess portfolio across columns, filtration, and single-use systems (formerly GE Healthcare Life Sciences). A full-stack incumbent that overlaps with AKBA on chromatography/synthesis columns and filtration for biomanufacturing.
• MilliporeSigma (Merck KGaA Life Science): Major bioprocess consumables and systems provider including tangential flow filtration, buffers, and process development tools. Directly overlaps with AKBA in biological buffers and downstream filtration for biologics.
• Sartorius AG: Global bioprocessing equipment and consumables leader covering upstream, downstream, and filtration. Competes with AKBA in tangential flow filtration and integrated bioprocess solutions for pharma and biologics manufacturers.
• Thermo Fisher Scientific: Diversified life-sciences platform with bioproduction offerings including single-use, filtration, and chromatography. Competes in the wider bioprocessing equipment market serving oligonucleotide and peptide manufacturers.

Direct peers

• Tosoh Bioscience: Specialist in liquid chromatography media, columns, and analytical instruments for biopolymer separations. Closely comparable to AKBA in chromatography/synthesis column offerings for nucleic-acid and peptide purification.
• Repligen Corporation: Pure-play bioprocessing company focused on tangential flow filtration and single-use solutions. Direct overlap with AKBA's TFF unit and integrated system approach for biologics manufacturing.
• Bio-Rad Laboratories: Provides chromatography resins, columns, and process analytical instruments used in bioprocessing. Comparable to AKBA in life-science separation and process instrumentation for pharma manufacturers.
• PeptiSystems: Swedish flow-through peptide synthesis technology provider in exclusive global partnership with AKBA. Directly tied through the integrated peptide synthesis solution and represents AKBA's closest strategic peer in peptide manufacturing equipment.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/711225

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Asahi Kasei Bioprocess America